A New Mutation Identified in an Imatinib and Nilotinib Resistant Chronic Myeloid Leukemia Patient
Hui Cheng, ChongMei Huang, HuiYing Qiu, WeiPing Zhang, Li Chen, XianMin Song, JianMin Yang and JianMin Wang*
Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China
- *Corresponding Author:
- Jianmin Wang
Department of Hematology
Changhai Hospital, Shanghai 200433, P.R. China
E-mail: [email protected]
Received date: November 23, 2015 Accepted date: February 24, 2016 Published date: February 27, 2016
Citation: Cheng H, Huang C, Qiu H, Zhang W, Chen L, et al. (2016) A New Mutation Identified in an Imatinib and Nilotinib Resistant Chronic Myeloid Leukemia Patient. Chemo Open Access 5:193. doi:10.4172/2167-7700.1000193
Copyright: © 2016 Cheng H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Chronic myeloid leukemia (CML) is a heterogeneous disease induced by BCR-ABL oncogene. Since the emergence of Tyrosine kinase inhibitors(TKIs), treatment of CML has been drastically changed. However, resistance and intolerance of TKIs have frequently been reported, especially in advanced-stage patients. The most critical reason for TKIs resistance is point mutations within the ABL1 kinase domain that interfere the binding of ABL1 with TKIs. The types and frequencies of mutations have been reported in different population. In this study, we identified a new mutation A2387G (N796S) within the BCR domain (exon 10) via next generation exon sequencing in an imatinib and nilotinib resistant CML patient.